Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589896 | 0.94 | — | — | |
| SCHEMBL60216 | 0.94 | — | — | |
| SCHEMBL3882554 | 0.94 | — | — | |
| Bromide SCHEMBL23306699 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL4719049 | 0.91 | — | — | |
| Bromide SCHEMBL1487603 | 0.91 | TSHR (0.35) | TSHRSMN1; SMN2ALDH1A1LAP3MAPK1 | |
| Hydrochloric Acid SCHEMBL28026792 | 0.91 | — | — | |
| Trimethylammonium SCHEMBL27701357 | 0.86 | TSHR (0.32) | TSHRSMN1; SMN2 | |
| Ether SCHEMBL28078517 | 0.81 | TSHR (0.30) | TSHRSMN1; SMN2 | |
| SCHEMBL5618574 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110293745-A1 | AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2265618-A2 | AURORA KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009114856-A2 | AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110293745-A1 | AURORA KINASE INHIBITORS | AURKA, AURKC, AURKB | TSHR 4399/4885SMN1; SMN2 4526/4885ALDH1A1 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.